Israel Englander Eloxx Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.24 - $0.58 $25,411 - $61,412	-105,883 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.4 - $0.72 $27,872 - $50,170	-69,681 Reduced 39.69%	105,883 $59,000
Q4 2021 Feb 14, 2022	SELL	$0.62 - $1.61 $61,214 - $158,960	-98,733 Reduced 35.99%	175,564 $123,000
Q3 2021 Nov 15, 2021	SELL	$1.22 - $2.0 $145,675 - $238,812	-119,406 Reduced 30.33%	274,297 $447,000
Q2 2021 Aug 16, 2021	BUY	$1.35 - $3.36 $531,499 - $1.32 Million	393,703 New	393,703 $783,000
Q1 2020 May 14, 2020	SELL	$1.96 - $7.96 $76,975 - $312,613	-39,273 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$3.19 - $7.56 $67,018 - $158,828	21,009 Added 115.03%	39,273 $289,000
Q3 2019 Nov 14, 2019	SELL	$4.37 - $9.91 $14,569 - $33,039	-3,334 Reduced 15.44%	18,264 $82,000
Q2 2019 Aug 15, 2019	SELL	$8.77 - $12.49 $466,511 - $664,393	-53,194 Reduced 71.12%	21,598 $215,000
Q2 2019 Aug 14, 2019	BUY	$8.77 - $12.49 $655,925 - $934,152	74,792 New	74,792 $503,000

Ticker ELOX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 86,656,200
Description
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis p...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.